OrthoPediatrics Posts Record Revenue Growth and First Positive Free Cash Flow
Event summary
- OrthoPediatrics reported full-year 2025 revenue of $236.3 million, up 15% from 2024.
- Achieved first quarter of positive free cash flow in company history with $10 million in Q4 2025.
- Revenue growth driven by 17% increase in Trauma and Deformity products and 13% increase in Scoliosis products.
- Adjusted EBITDA increased to $14.8 million for full year 2025, up from $8.5 million in 2024.
The big picture
OrthoPediatrics' strong financial performance in 2025 highlights its leadership in pediatric orthopedics. The company's ability to generate positive free cash flow for the first time signals improved operational efficiency. As it enters a 'super cycle' of new product launches, its strategic focus on market share expansion and profitability will be critical in sustaining growth amidst competitive industry dynamics.
What we're watching
- Revenue Growth Sustainability
- Whether OrthoPediatrics can maintain its 15% revenue growth rate in 2026, especially with guidance projecting slower growth of 11-13%.
- Cash Flow Improvement
- The pace at which the company can achieve breakeven free cash flow in 2026 after generating $10 million in Q4 2025.
- Product Innovation
- How upcoming innovative product launches will impact market share and revenue growth across Trauma, Deformity, and Scoliosis segments.
Related topics